<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271063</url>
  </required_header>
  <id_info>
    <org_study_id>CP-103</org_study_id>
    <nct_id>NCT00271063</nct_id>
  </id_info>
  <brief_title>Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia</brief_title>
  <official_title>Phase I/II Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Callisto Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Callisto Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II multi-center, open label, dose escalation study to identify the maximum
      tolerated dose (MTD) of liposomal annamycin and to evaluate the safety of liposomal annamycin
      in patients with refractory or relapsed acute lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/II, multi-center, open-label, dose escalation, MTD study of liposomal
      annamycin in refractory or relapsed ALL patients. Enrollment will occur in cohorts of
      approximately 3 patients with 10 additional patients enrolled at the MTD. The liposomal
      annamycin doses will be escalated in sequential cohorts. Four dose levels of liposomal
      annamycin are planned: 190, 230, 280, and 310 mg/m2/day.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2005</start_date>
  <completion_date type="Anticipated">April 2008</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of L-Annamycin</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study multi drug-resistant (MDR)-1 encoded P-170 glycoprotein expression and MDR-1 multidrug-resistant-associated protein (MRP), lung-resistance associated protein LRP), and breast cancer resistance protein (BCRP) mRNA levels</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the pharmacokinetics of annamycin and its metabolite, annamycinol.</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Acute Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Annamycin</intervention_name>
    <description>3-day IV infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of refractory or relapsed ALL (acute lymphocytic leukemia)

          -  Age greater than or equal to 15 years

          -  No chemotherapy, radiation, or major surgery within 2 weeks prior to first dose of
             study drug and recovered from toxic side effects of that therapy, unless treatment is
             indicated due to progressive disease.

          -  No investigational therapy within 4 weeks of first dose of study drug

          -  ECOG performance status (PS) 0 to 2.

          -  Adequate liver function

          -  Adequate renal function

          -  Signed informed consent

        Exclusion Criteria:

          -  Concommitant therapy that includes other chemotherapy that is or may be active against
             ALL (except central nervous system [CNS] therapy)

          -  Any condition which in the opinion of the investigator, places the subject at
             unacceptable risk if he/she were to participate in the study.

          -  Cardiac ejection fraction less than 40%

          -  Clinically relevant serious co-morbid medical conditions.

          -  Pregnant, lactating or not using adequate contraception.

          -  Known allergy to doxorubicin or anthracyclines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Jacob, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Callisto Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig C. Talluto, PhD, abd</last_name>
    <phone>212-297-0010</phone>
    <phone_ext>231</phone_ext>
    <email>ctalluto@callistopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Pinard, MS</last_name>
      <phone>718-920-2090</phone>
    </contact>
    <investigator>
      <last_name>Samir Parekh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Anderson, RN</last_name>
      <phone>716-845-8360</phone>
    </contact>
    <investigator>
      <last_name>Meir Wetzler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Thomas, RN, BSN, OCN</last_name>
      <phone>713-763-8776</phone>
    </contact>
    <investigator>
      <last_name>Hagop Kantarjian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2005</study_first_submitted>
  <study_first_submitted_qc>December 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2005</study_first_posted>
  <last_update_submitted>December 17, 2007</last_update_submitted>
  <last_update_submitted_qc>December 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2007</last_update_posted>
  <responsible_party>
    <name_title>Gary Jacob</name_title>
    <organization>Callisto Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Refractory or Relapsed Acute Lymphocytic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Annamycin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

